Samlyn Capital’s Pfizer PFE Stock Holding History

Samlyn Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,503,300	Closed	-$43.3M	–	110
2023 Q4	$43.3M	Buy	+1,503,300	New	+$45.4M	0.86%	36

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Samlyn Capital's PFE Position: Q1 2025 in Review

Samlyn Capital sold out of Pfizer (PFE) in Q1 2025, closing a stake of 7,291,751 shares — an estimated $193M sold.

Samlyn Capital first reported a position in PFE in Q4 2015 and held it in 8 quarters. The position peaked at $229M in Q3 2024. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

Samlyn Capital reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
Samlyn Capital sold 7,291,751 Pfizer shares in Q1 2025, an estimated $193M.
Samlyn Capital first reported a position in Pfizer in Q4 2015 and held it in 8 quarters.
Samlyn Capital's Pfizer position peaked at $229M in Q3 2024.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Samlyn Capital's 13F filing for Q1 2025, filed 15 May 2025.